ClinicalTrials.gov

History of Changes for Study: NCT03981146
A Phase II Trial Assessing Nivolumab in Strong Class II Expressing Microsatellite Stable Colorectal Cancer (ANICCA)
Latest version (submitted September 27, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 June 7, 2019 None (earliest Version on record)
2 October 21, 2019 Recruitment Status, Study Status, Contacts/Locations, Study Description and Oversight
3 March 27, 2020 Study Status and Contacts/Locations
4 June 15, 2020 Arms and Interventions, Study Description, Study Status, Study Identification, Eligibility and Conditions
5 November 3, 2020 Contacts/Locations and Study Status
6 November 5, 2020 Contacts/Locations and Study Status
7 September 14, 2021 Recruitment Status, Study Status, Contacts/Locations and Study Design
8 September 27, 2022 Study Status, References and Arms and Interventions
Comparison Format:

Scroll up to access the controls

Study NCT03981146
Submitted Date:  June 7, 2019 (v1)

Open or close this module Study Identification
Unique Protocol ID: RG_17-215
Brief Title: A Phase II Trial Assessing Nivolumab in Strong Class II Expressing Microsatellite Stable Colorectal Cancer (ANICCA)
Official Title: A Phase II Trial Assessing Nivolumab in Strong Class II Expressing Microsatellite Stable Colorectal Cancer
Secondary IDs: 2018-000318-39 [EudraCT Number]
40245896 [Registry Identifier: ISRCTN]
Open or close this module Study Status
Record Verification: April 2019
Overall Status: Not yet recruiting
Study Start: June 1, 2019
Primary Completion: December 1, 2020 [Anticipated]
Study Completion: December 1, 2027 [Anticipated]
First Submitted: May 9, 2019
First Submitted that
Met QC Criteria:
June 7, 2019
First Posted: June 10, 2019 [Actual]
Last Update Submitted that
Met QC Criteria:
June 7, 2019
Last Update Posted: June 10, 2019 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: University of Birmingham
Responsible Party: Sponsor
Collaborators: Bristol-Myers Squibb
Open or close this module Oversight
U.S. FDA-regulated Drug: No
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: this trial is an open-label, single arm, phase II, multicentre clinical trial to determine the rate of durable clinical benefit of nivolumab in patients with strong class II expressing microsatellite stable colorectal cancer.
Detailed Description:

Immuno-oncology is transforming the care of certain patients with cancer. Not all patients respond to these therapies however, and in some common cancers checkpoint blockade has failed to make any real impact. In 2014 there were over 41,000 new cases of colorectal cancer (CRC) in the UK and nearly 16,000 deaths from the disease, making it the second commonest cause of cancer death (Cancer Research UK Cancer Statistics Key Facts). 15% of patients with CRC develop it as a result of deficient mismatch repair (microsatellite instability - MSI): this cohort of patients respond well to PD-1/PD-L1 blockade as these tumours harbour a very high number of mutations thus increasing the likelihood of the presence of immunogenic neo-epitopes which elicit an immune response1. The majority of CRC patients, particularly those with metastatic disease (around 95%), do not display this hyper-mutator phenotype (microsatellite stable (MSS) CRC) and in these patients the results of PD-1/PD-L1 blockade have been disappointing.

In summary, MSS CRC patients with strong class II expression appears to represent immunologically a group of MSI-like MSS patients that may respond to usefully to the immunotherapy agent nivolumab as a single agent and thus a trial of nivolumab in patients with strong class II expression of their cancer cells appears to be highly justified.

Open or close this module Conditions
Conditions: Colorectal Cancer
Keywords: Strong Class II Microsatellite Status
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 2
Interventional Study Model: Single Group Assignment
Number of Arms: 1
Masking: None (Open Label)
Allocation: N/A
Enrollment: 36 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Nivolumab
Patients will receive 240mg of Nivolumab on a two weekly cycle for a maximum of two years.
Drug: Nivolumab
30 Minute IV Infusion
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Durable Clinical Benefit
[ Time Frame: Beginning of trial treatment to free of disease progression (104 weeks maximum) ]

patient will be defined as experiencing DCB if they remain free of disease progression at their third trial specific CT scan since treatment start date (i.e. at approximately 27 weeks) or at any CT scan after 27 weeks that shows the patient remains free of disease progression
Secondary Outcome Measures:
1. Objective response
[ Time Frame: trial treatment until disease progression (104 weeks maximum) ]

Objective response is the occurrence of CR or PR as the best overall response
2. Best Percentage Change in Sum of Target Lesions
[ Time Frame: Trial Treatment to disease progression (104 weeks maximum) ]

At each evaluation, the longest diameters of all selected target lesions will be measured and summed and the percentage change from the baseline measurement will be calculated. The best percentage change is the one that reflects either the greatest decrease or the least increase over the whole period of assessment.
3. Time to Maximal Response
[ Time Frame: Occurrence of CR or PR during the trial (104 weeks maximum) ]

This is defined as the time from commencement of trial treatment to the date of CT scan that first records the best objective response as per RECIST version 1.1.
4. Progression Free Survival Time
[ Time Frame: time from commencement of trial treatment to the date of CT scan when progressive disease first recorded (104 weeks maximum) ]

This is defined as the time from commencement of trial treatment to the date of CT scan when progressive disease first recorded or date of death without previously recorded progression.first records the best objective response as per RECIST version 1.1.
5. Overall Survival Time
[ Time Frame: Trial Treatment to date of death. ]

This is defined as the time from commencement of trial treatment to the date of death.
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

Inclusion Criteria:

  • Histologically confirmed locally advanced or metastatic MSS CRC with strong class II expression (greater than 50% cancer cell positivity for class II expression on immunohistochemistry).
    • Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (APPENDIX 1)
    • Age ≥ 18 years
    • Patients must have completed all standard of care therapy that the treating oncologist deems appropriate. Trial treatment as first line therapy is permitted if the patient has declined standard of care therapy.
    • CT scan of chest, abdomen, pelvis within 28 days of registration demonstrating unidimensionally measurable disease as per RECIST version 1.1 (APPENDIX 3).
    • Demonstrate adequate haematological function:
      • Platelet count ≥100 x 109 /L
      • Neutrophils ≥1.5 x 109/L
      • Haemoglobin ≥ 90 g/L
    • Demonstrate adequate hepatic function:
      • Serum bilirubin ≤1.5 x upper limit of normal (ULN)
      • Serum AST or ALT ≤2.5 x ULN or <5 x ULN in the presence of liver metastases
    • Demonstrate adequate renal function

      o Creatinine clearance <1.5 times ULN and >30ml/min (as per institutional standard).

    • Provision of signed and dated, written informed consent prior to any trial specific procedures, sampling and analyses.
    • Negative pregnancy test (female patients of reproductive potential). (Serum Test must be negative)
    • Patients must agree to the use of contraception as detailed in section 7.8

Exclusion Criteria:

  • Previous treatment with PD1/PDL1 inhibitors.
    • Untreated symptomatic brain or leptomeningeal metastatic disease.
    • Medical or psychiatric conditions compromising informed consent.
    • Any medical condition which, in the opinion of the Investigator, would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.
    • Administration of chemotherapy, radioactive or biological cancer therapy within 4 weeks prior to the first dose of trial therapy Patient has not recovered to CTCAE grade 1 or better from the Adverse Event (AE) due to cancer therapeutics administered more than 4 weeks earlier.
    • Active autoimmune disease that has required systemic treatment in past 2 years (i.e.

with use of disease modifying agents, corticosteroids or immunosuppressive drugs).

Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.

  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patient has risk factors for bowel obstruction or bowel perforation (examples include but not limited to a history of acute diverticulitis, intra-abdominal abscess and abdominal carcinomatosis).
  • Patient has a known history of other malignancy, unless the patient has undergone potentially curative therapy with no evidence of that disease for 3 years.
  • Has a history of non-infectious pneumonitis requiring steroids or has active pneumonitis.
  • Female patients that are either pregnant or breast feeding.
  • Male and female patients (of childbearing age) not willing to use adequate contraception.
  • Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
  • Patient is positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA (qualitative) is detected); patients with negative Hepatitis C antibody testing may not need RNA testing.
  • Known history of tuberculosis.
  • Patient has an active infection requiring therapy.
  • Has received a live vaccine within 30 days prior to the first dose of trial treatment.
  • Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
Open or close this module Contacts/Locations
Central Contact Person: ANICCA Trial Office
Telephone: 0121 414 6754
Email: anicca-classii@trials.bham.ac.uk
Study Officials: Gary Middleton, MB,BS,FRCP
Principal Investigator
University of Birmingham
Locations:
Open or close this module IPDSharing
Plan to Share IPD: No
Open or close this module References
Citations:
Links:
Available IPD/Information:

Scroll up to access the controls Scroll to the Study top

U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services